L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 ...
Q3 2025 Earnings Call Transcript October 28, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.11, ...
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the expansion of its Phase III ...
Petosemtamab plus FOLFOX: Most frequent treatment-emergent adverse events (TEAEs) regardless of causality (all Grades [G]/G3) were dermatitis acneiform (71%/0%), constipation (43%/0%), fatigue (43%/0% ...
Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Merus (MRUS) announced interim clinical data as of a July 29, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody ...
The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...
Biomarker testing is ushering in a novel era of therapy personalisation for gastroesophageal and colorectal cancers, ...
Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback